Rosetta launches first microRNA-based test
This article was originally published in Clinica
Executive Summary
Rosetta Genomics has launched its first microRNA-based diagnostic, miRview, which will be available through the firm's CLIA-certified laboratory in Philadelphia, Pennsylvania. The test differentiates squamous from non-squamous non-small cell lung cancer (NSCLC); this is important because certain drugs, such as Genentech/Roche's Avastin (bevacizumab), are less effective in squamous cell disease. In extreme cases, fatal bleeding can occur in squamous cell patients given these drugs. miRview received its first CLIA approval from the New York State Department of Health in July 2008 (see Clinica No 1317, p 18). The test has a sensitivity and specificity of 97% and 91%, respectively, in identifying squamous cell NSCLC, Rehovot, Israel-based Rosetta said.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.